Medicus Pharma (NASDAQ:MDCX) Receives Buy Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Medicus Pharma (NASDAQ:MDCX) in a research note released on Monday morning,Benzinga reports. They currently have a $27.00 price objective on the stock.

Separately, Zacks Research upgraded Medicus Pharma to a “hold” rating in a report on Monday, September 15th. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $23.50.

Medicus Pharma Price Performance

NASDAQ:MDCX opened at $2.51 on Monday. The firm has a market cap of $44.73 million and a PE ratio of -1.87. The firm has a 50 day simple moving average of $2.32 and a 200-day simple moving average of $3.27. Medicus Pharma has a 1-year low of $1.79 and a 1-year high of $8.94.

Medicus Pharma (NASDAQ:MDCX) last announced its earnings results on Monday, August 11th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). As a group, sell-side analysts expect that Medicus Pharma will post -1.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Medicus Pharma

Institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new stake in Medicus Pharma during the second quarter worth about $41,000. Osaic Holdings Inc. grew its holdings in shares of Medicus Pharma by 180.0% during the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after purchasing an additional 9,000 shares during the period. May Hill Capital LLC acquired a new stake in Medicus Pharma during the 2nd quarter worth approximately $107,000. SeaCrest Wealth Management LLC acquired a new stake in Medicus Pharma during the 2nd quarter worth approximately $139,000. Finally, Private Advisor Group LLC purchased a new position in Medicus Pharma in the first quarter valued at approximately $211,000.

About Medicus Pharma

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.